RxDoctor Payments Data

Adam Haussler, MD

Internal Medicine · Kearney, NENPI 1417290560

Payments from drug & device makers

$2,134in general payments, 2019–2025

Across 146 payments — averaging $14.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$704
  • AstraZeneca$384
  • Novo Nordisk$224
  • GSK$204
  • Lilly USA, LLC$96
  • Pfizer$78
  • plus $443 from 14 others

What the payments were for

  • Food & beverage$2,134100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,134 in reported general payments places this provider in the 85th percentile of 570 internal medicine providers in Nebraska.

See all internal medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$166,388
Medicare patients
554
Services billed
2,307

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin119$92,516
MounjaroTirzepatide40$42,158
OzempicSemaglutide42$38,850
EliquisApixaban58$35,135
FarxigaDapagliflozin Propanediol25$15,545
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$13,404
XareltoRivaroxaban14$13,371
TrulicityDulaglutide13$13,112
MyrbetriqMirabegron32$10,017
Repatha SureclickEvolocumab15$8,123
ShingrixVaricella-Zoster Ge/As01b/Pf32$7,010
LivaloPitavastatin Calcium20$6,360
Varenicline Tartrate12$3,538
Potassium Chloride151$2,825
Atorvastatin Calcium271$2,409

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$96$55,27053 claims
Novo NordiskOzempic, Novolog$224$40,20759 claims
PfizerEliquis$78$35,13558 claims
AstraZenecaFarxiga, Breztri Aerosphere$384$28,94946 claims
Johnson & JohnsonXarelto$28$13,37114 claims
GSKShingrix$204$7,01032 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 570 internal medicine providers in Nebraska.

Other internal medicine in Kearney

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →